Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.
about
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgeryClinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentratesSclerotherapy Of Esophageal Varices In Severe Hemophilia A Patient And High Titer Inhibitor--Case Report.Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.Hemophilia care in India: a review and experience from a tertiary care centre in uttar pradesh.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects.Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.Recombinant activated factor VII in clinical practice: a 2014 update.Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.Optimising musculoskeletal care for patients with haemophilia.Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors.The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors.Hemophilic chronic synovitis: therapy of hemarthrosis using endovascular embolization of knee and elbow arteries.Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitorsThe efficacy of bypassing agents in surgery of hemophilia patients with inhibitors.Port-A-Cath infection causes inhibitor recurrence after initial successful ITI.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen.Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A.How I treat inhibitors in haemophilia.Guidelines for the management of hemophilia.Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.
P2860
Q24188177-388755EA-799F-4B0A-95DD-4D99C8CC8A57Q27026389-70B7FB57-8618-44DA-A197-2EEDD1049AB4Q33429529-1B7AB8E7-63AA-4ADC-A746-E65F91112D1EQ35069871-1A9A1AA1-40AE-448A-A92E-ECBFD1403B7BQ35163225-E66E7A40-256B-4167-904D-5A35A79C6E4AQ37185097-44274BC6-ED8D-4686-88CC-62E454DE7503Q37835878-0EF716B0-E0FD-4296-AE65-FE1CB017DCCDQ37845931-DD5EC3FC-6140-4F1B-BF8E-3DDFDCD9644CQ38038332-EE2B9BEA-7BD2-4892-B446-BB58F4DBDA2CQ38044492-B4468762-B2A4-4776-A0C2-0424074D888CQ38060224-C6B81BE7-2911-4DEE-B8E5-0AF0B06B4D03Q38228494-53CF2994-D297-4E75-AE7A-C0CBFC709B9EQ38546790-D9243580-6037-46CF-84A5-640F379D265FQ38672487-D01B218E-BC1E-4711-A57F-6F48B0AC06AFQ38682218-4D98D874-C53F-40CA-B6BB-AB98158A8321Q39420691-3C263970-A901-4AC1-872F-AB0F2F292808Q39675759-4F6EDCB1-A7FD-428F-8427-9C517156CD6AQ40074647-87849EE0-DD68-4084-841D-4CF52639D2EBQ40539842-C9BC517A-B913-4248-8F50-F9061B64B52DQ41210614-FB749B5D-BBF4-41B4-8A63-A66C587124B7Q44578616-002C91F6-6FDC-45F8-B95E-F86BC8A1B9EEQ45838031-D33FC278-DDC7-43DA-90A0-7889FCAFB7D8Q45855177-254BF497-140B-4224-B285-260223535CD9Q45862378-C214FFCB-86C4-4FEE-8382-85A4E9D7AB27Q45865332-7C1C14AF-DD84-4EEC-A2E0-2A4008FAC12BQ45867897-2F823D53-38A3-4DC8-B681-9F3A7F3D0621Q45879927-CC77AD96-E610-419B-A54B-C68878ED856FQ45880345-F2A80499-4122-45F9-A6A8-514E6E85050DQ45886119-7052CEAA-2952-47AE-B45B-EF4721F5BFC1
P2860
Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Consensus protocol for the use ...... ilic patients with inhibitors.
@en
Consensus protocol for the use of recombinant activated factor VII [eptacog alfa
@nl
type
label
Consensus protocol for the use ...... ilic patients with inhibitors.
@en
Consensus protocol for the use of recombinant activated factor VII [eptacog alfa
@nl
prefLabel
Consensus protocol for the use ...... ilic patients with inhibitors.
@en
Consensus protocol for the use of recombinant activated factor VII [eptacog alfa
@nl
P2093
P1433
P1476
Consensus protocol for the use ...... ilic patients with inhibitors.
@en
P2093
C A Ludlam
E G D Tuddenham
J Ingerslev
N J Goddard
P L F Giangrande
P304
P356
10.1111/J.1365-2516.2008.01952.X
P577
2009-02-01T00:00:00Z